Pure Global
NCT06339034

Repurposing Lithium for Parkinson's Disease: a RCT

Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Randomized Controlled Trial
State University of New York at Buffalo·Phase 1/2·ClinicalTrials.gov·dietary supplementNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Lithium
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
State University of New York at Buffalo
Location
Williamsville, United States of America
Timeline & enrollment
Phase
Phase 1/2
Start date
Jun 01, 2024
End date
Oct 01, 2025
Enrollment
20 participants
Primary outcome

MRI-derived free water (FW) levels.,Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression,Serum neurofilament light chain (NfL)

Summary

This study will examine the effects of lithium 20mg/day compared to placebo on MRI and
 blood-based biomarkers among 20 early-stage Parkinson's disease patients.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06339034
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06339034 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.